Sucrosomial(®) Iron: A New Generation Iron for Improving Oral Supplementation.
Sucrosomial(®) Iron: A New Generation Iron for Improving Oral Supplementation.
复制标题
DOI：
10.3390/ph11040097
复制
发表时间：
2018-10-04
期刊：
影响因子：
--
通讯作者：
Muñoz M
中科院分区：
文献类型：
--
作者：
Gómez-Ramírez S;Brilli E;Tarantino G;Muñoz M
铁缺乏症（ID）通常用口服铁盐治疗，但高达50%的患者抱怨胃肠道副作用，导致治疗依从性降低。静脉注射（IV）铁制剂越来越安全，但仍存在输注、超敏反应的风险，需要静脉通路和输注监测。Sucrosomial® Iron（SI）是一种创新的口服铁制剂，其中焦磷酸铁受到磷脂双层和蔗糖酯基质（sucrosome）的保护，通过细胞旁和跨细胞途径（M细胞）吸收。这赋予了SI独特的结构、物理化学和药代动力学特征，以及其高铁生物利用度和优异的胃肠道耐受性。现有证据的分析支持口服SI铁作为ID治疗的有效选择，其比口服铁盐更有效和耐受。SI还在通常接受IV铁剂的患者中证明了类似的有效性，风险较低（例如，慢性肾病、癌症、减肥手术）。因此，口服SI成为治疗ID的有价值的第一选择，特别是对于对铁盐不耐受的受试者或铁盐无效的受试者。此外，在不同的患者人群中，SI也应被视为IV铁剂的替代品，用于初始和/或维持治疗。
Iron deficiency (ID) is usually treated with oral iron salts, but up to 50% of patients complain of gastrointestinal side effects, leading to reduced compliance with treatment. Intravenous (IV) iron formulations are increasingly safe, but there is still a risk of infusion, hypersensitivity reactions and the need for venous access and infusion monitoring. Sucrosomial® Iron (SI) is an innovative oral iron formulation in which ferric pyrophosphate is protected by a phospholipid bilayer plus a sucrester matrix (sucrosome), which is absorbed through para-cellular and trans-cellular routes (M cells). This confers SI’s unique structural, physicochemical and pharmacokinetic characteristics, together with its high iron bioavailability and excellent gastrointestinal tolerance. The analysis of the available evidence supports oral SI iron as a valid option for ID treatment, which is more efficacious and tolerable than oral iron salts. SI has also demonstrated a similar effectiveness, with lower risks, in patients usually receiving IV iron (e.g., chronic kidney disease, cancer, bariatric surgery). Thus, oral SI emerges as a valuable first option for treating ID, especially for subjects with intolerance to iron salts or those for whom iron salts are inefficacious. Moreover, SI should also be considered as an alternative to IV iron for initial and/or maintenance treatment in different patient populations.
登录
查看更多内容
DOI：
10.3324/haematol.13255
发表时间：
2008-12-01
期刊：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
影响因子：
--
作者：
Bergamaschi, Gaetano;Markopoulos, Konstantinos;Corazza, Gino Roberto
通讯作者：
Corazza, Gino Roberto
影响因子：
3.2
作者：
Darba, Josep;Ascanio, Meritxell
通讯作者：
Ascanio, Meritxell
影响因子：
19.6
作者：
Agarwal R;Kusek JW;Pappas MK
通讯作者：
Pappas MK
影响因子：
8
作者：
Dignass, Axel U.;Gasche, Christoph;Vavricka, Stephan
通讯作者：
Vavricka, Stephan
影响因子：
1.9
作者：
Ciudin, Andreea;Simo-Servat, Olga;Mesa, Jordi
通讯作者：
Mesa, Jordi